Molecular mediators of hepatic steatosis and liver injury
- PMID: 15254578
- PMCID: PMC449757
- DOI: 10.1172/JCI22422
Molecular mediators of hepatic steatosis and liver injury
Abstract
Obesity and its associated comorbidities are among the most prevalent and challenging conditions confronting the medical profession in the 21st century. A major metabolic consequence of obesity is insulin resistance, which is strongly associated with the deposition of triglycerides in the liver. Hepatic steatosis can either be a benign, noninflammatory condition that appears to have no adverse sequelae or can be associated with steatohepatitis: a condition that can result in end-stage liver disease, accounting for up to 14% of liver transplants in the US. Here we highlight recent advances in our understanding of the molecular events contributing to hepatic steatosis and nonalcoholic steatohepatitis.
Figures



References
-
- Neuschwander-Tetri B, Caldwell S. Nonalcoholic steatohepatitis:summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219. - PubMed
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003;98:960–967. - PubMed
-
- Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002;346:1221–1231. - PubMed
-
- Marchesini G, et al. Nonalcoholic fatty liver disease a feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850. - PubMed
-
- Day CP, James OFW. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114:842–845. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical